Posted by Michael Wonder on 09 Feb 2023
Availability of Sanofi’s Nexviadyme (avalglucosidase alfa) provides NHS with new treatment for Pompe disease
8 February 2023 - Sanofi announced today that health care specialists and patients living with Pompe disease will now have access to a new treatment – Nexviadyme (avalglucosidase alfa) – providing the NHS with a NICE approved, long-term enzyme replacement therapy.
Prior to the availability of avalglucosidase alfa, only one treatment for Pompe disease has been available (alglucosidase alfa, branded Myozyme).
